AI Bias Analysis
4 models · Takes ~15 seconds
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- Years ago, a practice operations leader told me that every patient encounter -- no matter how urgent -- was an opportunity to capture a quality metric. She referred to this as "in-reach," complimenting outreach to patients...
(MedPage Today) -- LONDON -- Baricitinib (Olumiant) failed to show noninferiority to tumor necrosis factor (TNF) inhibitors for venous thromboembolism (VTE) risk in FDA-required postmarketing studies, a researcher reported here. In two large...
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
